Robert C. Goeltz II Sells 3,594 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) Stock

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) CFO Robert C. Goeltz II sold 3,594 shares of the firm's stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total value of $53,910.00. Following the completion of the transaction, the chief financial officer now directly owns 60,138 shares of the company's stock, valued at $902,070. The trade was a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Arcus Biosciences Trading Down 0.5 %

Shares of Arcus Biosciences stock traded down $0.07 during trading hours on Friday, reaching $15.06. 385,838 shares of the company's stock were exchanged, compared to its average volume of 487,319. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -4.78 and a beta of 0.88. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. Arcus Biosciences, Inc. has a 52-week low of $13.52 and a 52-week high of $20.31. The company has a fifty day moving average of $15.94 and a 200-day moving average of $16.02.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.06) by $0.06. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The firm had revenue of $48.00 million for the quarter, compared to analyst estimates of $38.95 million. During the same period last year, the company earned ($0.94) EPS. The firm's quarterly revenue was up 50.0% on a year-over-year basis. Sell-side analysts forecast that Arcus Biosciences, Inc. will post -3.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

RCUS has been the topic of a number of research reports. Wedbush reissued an "outperform" rating and issued a $36.00 price objective on shares of Arcus Biosciences in a research note on Thursday, November 7th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcus Biosciences in a research report on Thursday, October 3rd. Wells Fargo & Company initiated coverage on Arcus Biosciences in a research report on Tuesday, October 8th. They set an "overweight" rating and a $29.00 price objective for the company. HC Wainwright reiterated a "neutral" rating and set a $20.00 target price on shares of Arcus Biosciences in a report on Wednesday, November 6th. Finally, Barclays raised their price target on Arcus Biosciences from $25.00 to $29.00 and gave the stock an "overweight" rating in a research report on Friday, October 25th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $34.00.

Institutional Investors Weigh In On Arcus Biosciences

A number of institutional investors have recently bought and sold shares of RCUS. JPMorgan Chase & Co. boosted its holdings in shares of Arcus Biosciences by 2.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 43,685 shares of the company's stock valued at $668,000 after purchasing an additional 1,117 shares during the last quarter. Barclays PLC raised its position in shares of Arcus Biosciences by 49.0% in the 3rd quarter. Barclays PLC now owns 118,693 shares of the company's stock worth $1,816,000 after buying an additional 39,015 shares during the period. Y Intercept Hong Kong Ltd grew its position in Arcus Biosciences by 100.6% during the third quarter. Y Intercept Hong Kong Ltd now owns 23,581 shares of the company's stock valued at $361,000 after acquiring an additional 11,827 shares during the period. Jane Street Group LLC increased its stake in Arcus Biosciences by 59.8% during the third quarter. Jane Street Group LLC now owns 217,041 shares of the company's stock worth $3,319,000 after acquiring an additional 81,193 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its holdings in shares of Arcus Biosciences by 32.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,437,073 shares of the company's stock worth $37,263,000 after purchasing an additional 603,222 shares during the period. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.